Table 2

Demographic features of CF transplant recipients with chronic HEV infection

Subject 1Subject 2Subject 3
Age (years) at time of HEV detection404136
Biological sexMaleMaleFemale
CFTR mutationF508del/F508delF508del/F508delF508del/F508del
Organ transplantedLungLungLung
Months since transplantation at time of HEV detection2491111
Induction therapyRabbit antithymocyte globulinsRabbit antithymocyte globulinsRabbit antithymocyte globulins
Immunosuppressive therapyTacrolimus trough target 8–10 μg/mL/mycophenolate mofetil 1 g two times per day/prednisone 5 mgTacrolimus trough target 8–10 μg/mL/mycophenolate mofetil 1 g two times per day/prednisone 5 mgTacrolimus trough target 8–10 μg/mL/mycophenolate mofetil 1 g two times per day/prednisone 5 mg
Blood product receiptPacked red blood cells and irradiated platelets at time of lung transplantation. None after transplantPacked red blood cells and irradiated platelets at time of lung transplantation. None after transplantPacked red blood cells and irradiated platelets at time of lung transplantation. None after transplant
CF-related comorbiditiesPancreatic insufficiency, Pseudomonas aeruginosa colonisation, DIOS, CF-related diabetesPancreatic insufficiency, Pseudomonas aeruginosa colonisation, DIOSPancreatic insufficiency, Pseudomonas aeruginosa colonisation, chronic rhinosinusitis, CF-related diabetes
Additional post-transplant-related comorbiditiesChronic kidney diseaseDiabetes mellitus, chronic kidney diseaseChronic lung allograft dysfunction
OutcomeChronic HEV encephalopathy and deathObservation due to ongoing HEV IgM+ and HEV RT-PCR+, intolerance to therapy, increasing transaminases and declining renal functionObservation due to recurrence post-treatment and reluctance to restart therapy owing to intolerance
  • CF, cystic fibrosis; DIOS, distal intestinal obstruction syndrome; HEV, hepatitis E virus.